Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.
The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.
The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.
NEW YORK – After rising 9 percent in October, the 360Dx Top 30 continued its upward momentum last month, rising an additional 9 percent in November. The 360Dx Top 30 outpaced the broader markets as ...
NEW YORK – Precision oncology firm Cleveland Diagnostics announced Monday that its IsoPSA test for prostate cancer has received approval from the US Food and Drug Administration. The blood-based test ...
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.
The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.
The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback